Trending News
News

News
InNexus Announces new EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
Company targets another large product and continues expansion of antibody therapeutics pipeline.

News
Canopus BioPharma Announces Positive Results in Human Study of Peptide Cancer Vaccine
Study analyzed at Southern Research Institute shows human antibodies generated by Canopus’s peptides have anti-cancer properties.

News
NIH Scientists Identify Link between Brain Systems Implicated in Schizophrenia
The finding suggests that schizophrenia could result from a malfunction anywhere in the link between the three distinct brain circuits.

News
IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.

News
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
The collaboration will apply Deciphera's phylomechanics platform with Lilly's expertise to study B-Raf kinase inhibitors for cancer treatments.

News
Neovacs and BMD Announce OSEO Innovation Grant for Theranostics Project in Rheumatoid Arthritis
The companies have received a €7.9 million grant to support Tracker, a theranostics project concerning rheumatoid arthritis.

News
Luminex and BD Sign Agreement to Create Diagnostic Tests for Cancer
Collaboration will target development and marketing of new tools to enhance early cancer detection and intervention.

News
Study Reveals Link between Apobec3 Gene and Neutralizing Antibody Response to Retrovirus
New evidence strengthens the link between a host-cell gene Apobec3 and the production of neutralizing antibodies to retroviruses.

News
AssureRx Enters Into Strategic Relationship with Diamond Healthcare Corporation
AssureRx gets access to Diamond's managerial and clinical expertise, accelerating the development of AssureRx’s personalized medicine product for behavioral healthcare.

News
Teva Pharmaceutical Industries Extends Collaboration with Proteologics by Licensing Three Programs
Proteologics will discover and conduct early development of cancer treatments, while Teva will proceed with later stages of development and commercialization of the products.
Advertisement